Oral tacrolimus for pediatric steroid-resistant ulcerative colitis

Journal of Crohn's and Colitis

Volumn 8, Issue 1, 2014, Pages 64-69

  Navas Lopez V M ^a   Blasco Alonso, J ^a   Serrano Nieto, M J ^a   Giron Fernandez Crehuet F ^a   Argos Rodriguez, M D ^a   Sierra Salinas, C ^a  

^a HOSPITAL MATERNO INFANTIL   (Spain)

Author keywords

Children; ; Paediatric; Steroids; ; Surgery; ; Tacrolimus; ; Ulcerative colitis;

Indexed keywords

AMINOSALICYLATE; AZATHIOPRINE; CORTICOSTEROID; GASTROINTESTINAL AGENT; INFLIXIMAB; MERCAPTOPURINE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COLON RESECTION; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; TREATMENT DURATION; ULCERATIVE COLITIS;

CHILDREN;; PAEDIATRIC; STEROIDS;; SURGERY;; TACROLIMUS;; ULCERATIVE COLITIS;;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; COLECTOMY; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEROIDS; TACROLIMUS;

EID: 84890130421     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.006     Document Type: Article

References (43)

1. Turner D., Walsh C.M., Steinhart A.H., Griffiths A.M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5:103-110.
2. Turner D., Walsh C.M., Benchimol E.I., Mann E.H., Thomas K.E., Chow C., et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008, 57:331-338.
3. Turner D. Severe acute ulcerative colitis: the pediatric perspective. Dig Dis 2009, 27:322-326.
4. De Oca J., Vilar L., Castellote J., Sánchez Santos R., Parés D., Biondo S., et al. Immunomodulation with tacrolimus (FK 506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev Esp Enferm Dig 2003, 95:459-464.
5. Kelly D., Jara P., Rodeck B., Lykavieris P., Burdelski M., Becker M., et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 2004, 364:1054-1061.
6. Hernández F., López Santamaría M., Gámez M., Murcia J., Leal N., Prieto G., et al. Results of an intestinal transplantation program in Spain. Five years later. Cir Pediatr 2004, 17:145-148.
7. Plosker G.L., Foster R.H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000, 59(2):323-389.
8. Gulati S., Prasad N., Sharma R.K., Kumar A., Gupta A., Baburaj V.P. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008, 23(3):910-913.
9. Larsen F.S., Vainer B., Eefsen M., Bjerring P.N., Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007, 13:3232-3236.
10. Bousvaros A., Leichtner A.M., Book L., Shigeoka A., Bilodeau J., Semeao E., et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996, 111(1):237-243.
11. Chow D., Leong R. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2007, 6(5):479-485.
12. Turner D., Otley A.R., Mack D., de Bruijne J., Uusoue K., Walter T., et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 2007, 133:423-432.
13. Turner D., Hyams J., Markowitz J., Lerer T., Mack D.R. Evans J et al Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009, 15(8):1218-1223.
14. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
15. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
16. Turner D., Seow C.H., Greenberg G.R., Griffiths A.M., Silverberg M.S., Steinhart A.H. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7(10):1081-1088.
17. Turner D., Griffiths A. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011, 17(1):440-449.
18. Turner D., Mack D., Leleiko N., Walters T.D., Uusoue K., Leach S.T., et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010, 138(7):2282-2291.
19. De Iudicibus S., Stocco G., Martelossi S., Londero M., Ebner E., Pontillo A., et al. Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases. J Clin Gastroenterol 2011, 45(1):e1-e7.
20. De Iudicibus S., Franca R., Martelossi S., Ventura A., Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 2011, 17(9):1095-1108.
21. Kabakchiev B., Turner D., Hyams J., Mack D., Leleiko N., Crandall W., et al. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010, 5(9):e13085. [pii].
22. Lawlor G., Moss A.C. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. Inflamm Bowel Dis 2010, 16(9):1620-1627.
23. Ayre K., Warren B.F., Jeffery K., Travis S.P. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis 2009, 3(3):141-148.
24. Turner D., Travis S.P., Griffiths A.M., Ruemmele F.M., Levine A., Benchimol E.I., et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011, 106(4):574-588.
25. Gupta S., Keshavarzian A., Hodgson H.J. Cyclosporin in ulcerative colitis. Lancet 1984, 2(8414):1277-1278.
26. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330(26):1841-1845.
27. Laharie D., Bourreille A., Branche J., Allez M., Bouhnik Y., Filippi J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012, 380(9857):1909-1915.
28. Castro M., Papadatou B., Ceriati E., Knafelz D., De Angelis P., Ferretti F., et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg 2007, 392(2):161-164.
29. Ramakrishna J., Langhans N., Calenda K., Grand R.J., Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1996, 22(3):296-302.
30. Socha P., Wawer Z., Ryzko J., Orłowska E., Szczepański M., Kierkus J., et al. Efficacy and safety of cyclosporine in the treatment of inflammatory bowel disease in children-a retrospective study. Med Wieku Rozwoj 2006, 10(2):429-435.
31. Barabino A., Torrente F., Castellano E., Gandullia P., Calvi A., Cucchiara S., et al. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment Pharmacol Ther 2002, 16(8):1503-1507.
32. Treem W.R., Cohen J., Davis P.M., Justinich C.J., Hyams J.S. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995, 38(5):474-479.
33. Benkov K.J., Rosh J.R., Schwersenz A.H., Janowitz H.D., LeLeiko N.S. Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994, 19(3):290-294.
34. Kirschner B.S., Whitington P.F., Malfeo-Klein R. Experience with cyclosporine A (CyA) in severe non-specific ulcerative colitis. Pediatr Res 1989, 25:A117.
35. Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S., et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012, 10(4):391-399.
36. Bousvaros A., Wang A., Leichtner A.M. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996, 23(3):329-333.
37. Bousvaros A., Kirschner B.S., Werlin S.L., Parker-Hartigan L., Daum F., Freeman K.B., et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000, 137(6):794-799.
38. Ziring D.A., Wu S.S., Mow W.S., Martin M.G., Mehra M., Ament M.E. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007, 45(3):306-311.
39. Watson S., Pensabene L., Mitchell P., Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011, 17(1):22-29.
40. Ogata H., Matsui T., Nakamura M., Iida M., Takazoe M., Suzuki Y., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262.
41. Ogata H., Kato J., Hirai F., Hida N., Matsui T., Matsumoto T., et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012, 18(5):803-808.
42. Schmidt K.J., Herrlinger K.R., Emmrich J., Barthel D., Koc H., Lehnert H., et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Ther 2013, 37(1):129-136.
43. Herrlinger K.R., Koc H., Winter S., Teml A., Stange E.F., Fellermann K., et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther 2011, 89(3):422-428.